Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLA1QD)

Drug Name

MB-101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Recurrent glioblastoma	2A00.00	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin 13 receptor alpha-2 (IL13RA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tralokinumab	DM6ENSJ	Atopic dermatitis	EA80	Approved	[3]
ICT-107	DMBIZ7H	Brain cancer	2A00	Phase 3	[4]
ABT-308	DM6WN2D	Eosinophilic esophagitis	DA24.1	Phase 2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 13 receptor alpha-2 (IL13RA2)	TTMPZ7V	I13R2_HUMAN	Immunomodulator	[2]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94.
4	Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)